Ibrutinib ' Treatment of Choice ' in Waldenstrom Macroglobulinemia Ibrutinib ' Treatment of Choice ' in Waldenstrom Macroglobulinemia

Longer-term results from a pivotal study have established ibritinib as one of the most effective monotherapies for this disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news